论文部分内容阅读
目的:分析恩替卡韦联合胸腺肽治疗乙肝肝硬化的疗效及对患者纤维化指标的影响。方法:选择于2012年11月~2014年11月间接受治疗的乙肝肝硬化患者76例作为研究对象,按照随机数表法将所有入组患者分为:接受单纯恩替卡韦治疗的对照组,接受恩替卡韦联合胸腺肽治疗的观察组,每组各38例。比较两组患者的血清HBV-DNA载量及肝功能、肝纤维化指标等差异。结果:观察组患者接受治疗后的血清HBV-DNA载量、ALT、AST水平均明显低于对照组患者(P<0.05);观察组患者接受治疗后的血清HA、LN、C-IV水平均明显低于对照组患者(P<0.05)。结论:恩替卡韦联合胸腺肽可以有效抑制乙肝肝硬化患者的病毒复制,优化肝功能的同时降低纤维化程度。
Objective: To analyze the curative effect of entecavir and thymosin on hepatitis B cirrhosis and its influence on the fibrosis index of patients. Methods: Seventy-six patients with hepatitis B cirrhosis who were treated from November 2012 to November 2014 were selected as study subjects. According to the random number table, all patients were divided into three groups: control group receiving entecavir alone and entecavir Thymopeptide treatment in the observation group, 38 cases in each group. The serum HBV-DNA load, liver function and liver fibrosis indexes of two groups were compared. Results: Serum HBV-DNA load, ALT and AST levels in the observation group were significantly lower than those in the control group (P <0.05). The serum levels of HA, LN and C-IV in the observation group were significantly lower than those in the control group Significantly lower than the control group patients (P <0.05). Conclusion: Entecavir combined with thymosin can effectively inhibit viral replication in patients with hepatitis B cirrhosis, optimize liver function and reduce the degree of fibrosis.